Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus
The treatment of Type 2 Diabetes Mellitus (T2DM) consists primarily of oral antidiabetic drugs (OADs) that stimulate insulin secretion, such as sulfonylureas (SUs) and reduce hepatic glucose production (e.g., biguanides), among others. The marked inter-individual differences among T2DM patients’ res...
Main Authors: | Hector E. Sanchez-Ibarra, Luisa M. Reyes-Cortes, Xian-Li Jiang, Claudia M. Luna-Aguirre, Dionicio Aguirre-Trevino, Ivan A. Morales-Alvarado, Rafael B. Leon-Cachon, Fernando Lavalle-Gonzalez, Faruck Morcos, Hugo A. Barrera-Saldaña |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2018.00320/full |
Similar Items
-
The role of pharmacogenetics in the treatment of diabetes mellitus
by: Topić Elizabeta
Published: (2014-01-01) -
Clinical and statistical consideration in personalized medicine /
by: Carini, Claudio, et al.
Published: (2014) -
Sulfonylureas or biguanides is associated with a lower risk of rheumatoid arthritis in patients with diabetes: A nationwide cohort study
by: Yu-Jih Su, et al.
Published: (2022-07-01) -
INTEGRATING PHARMACOGENOMICS INTO CLINICAL PRACTICE
by: Gurinder Johal, et al.
Published: (2016-05-01) -
Establishment of a Pharmacogenetics Service Focused on Optimizing Existing Pharmacogenetic Testing at a Large Academic Health Center
by: Amy L. Pasternak, et al.
Published: (2020-10-01)